192 related articles for article (PubMed ID: 18955031)
1. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
[TBL] [Abstract][Full Text] [Related]
2. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants of Kv1.5 channel block by diphenyl phosphine oxide-1.
Du YM; Zhang XX; Tu DN; Zhao N; Liu YJ; Xiao H; Sanguinetti MC; Zou A; Liao YH
J Mol Cell Cardiol; 2010 Jun; 48(6):1111-20. PubMed ID: 20184887
[TBL] [Abstract][Full Text] [Related]
4. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3.
Felix JP; Bugianesi RM; Schmalhofer WA; Borris R; Goetz MA; Hensens OD; Bao JM; Kayser F; Parsons WH; Rupprecht K; Garcia ML; Kaczorowski GJ; Slaughter RS
Biochemistry; 1999 Apr; 38(16):4922-30. PubMed ID: 10213593
[TBL] [Abstract][Full Text] [Related]
5. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.
Regan CP; Wallace AA; Cresswell HK; Atkins CL; Lynch JJ
J Pharmacol Exp Ther; 2006 Feb; 316(2):727-32. PubMed ID: 16243963
[TBL] [Abstract][Full Text] [Related]
6. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels.
Eldstrom J; Wang Z; Xu H; Pourrier M; Ezrin A; Gibson K; Fedida D
Mol Pharmacol; 2007 Dec; 72(6):1522-34. PubMed ID: 17872968
[TBL] [Abstract][Full Text] [Related]
7. Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase.
Gong YZ; Ding WG; Wu J; Tsuji K; Horie M; Matsuura H
Eur J Pharmacol; 2008 Dec; 600(1-3):18-25. PubMed ID: 18930721
[TBL] [Abstract][Full Text] [Related]
8. Modeling the binding modes of Kv1.5 potassium channel and blockers.
Yang Q; Du L; Wang X; Li M; You Q
J Mol Graph Model; 2008 Sep; 27(2):178-87. PubMed ID: 18485768
[TBL] [Abstract][Full Text] [Related]
9. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.
Ravens U; Wettwer E
Cardiovasc Res; 2011 Mar; 89(4):776-85. PubMed ID: 21159668
[TBL] [Abstract][Full Text] [Related]
10. Interaction of propofol with voltage-gated human Kv1.5 channel through specific amino acids within the pore region.
Kojima A; Ito Y; Ding WG; Kitagawa H; Matsuura H
Eur J Pharmacol; 2015 Oct; 764():622-632. PubMed ID: 26256861
[TBL] [Abstract][Full Text] [Related]
11. Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.
Blass BE; Fensome A; Trybulski E; Magolda R; Gardell SJ; Liu K; Samuel M; Feingold I; Huselton C; Jackson CM; Djandjighian L; Ho D; Hennan J; Janusz JM
J Med Chem; 2009 Nov; 52(21):6531-4. PubMed ID: 19888755
[TBL] [Abstract][Full Text] [Related]
12. Regulation of human cardiac Kv1.5 channels by extracellular acidification.
Wang S; Ding WG; Bai JY; Toyoda F; Wei MJ; Matsuura H
Pflugers Arch; 2016 Nov; 468(11-12):1885-1894. PubMed ID: 27796577
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.
Trotter BW; Nanda KK; Kett NR; Regan CP; Lynch JJ; Stump GL; Kiss L; Wang J; Spencer RH; Kane SA; White RB; Zhang R; Anderson KD; Liverton NJ; McIntyre CJ; Beshore DC; Hartman GD; Dinsmore CJ
J Med Chem; 2006 Nov; 49(24):6954-7. PubMed ID: 17125248
[TBL] [Abstract][Full Text] [Related]
14. Novel alpha-KTx sites in the BK channel and comparative sequence analysis reveal distinguishing features of the BK and KV channel outer pore.
Giangiacomo KM; Becker J; Garsky C; Schmalhofer W; Garcia ML; Mullmann TJ
Cell Biochem Biophys; 2008; 52(1):47-58. PubMed ID: 18815746
[TBL] [Abstract][Full Text] [Related]
15. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.
Decher N; Kumar P; Gonzalez T; Pirard B; Sanguinetti MC
Mol Pharmacol; 2006 Oct; 70(4):1204-11. PubMed ID: 16835355
[TBL] [Abstract][Full Text] [Related]
16. Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231.
Ehrlich JR; Ocholla H; Ziemek D; Rütten H; Hohnloser SH; Gögelein H
J Cardiovasc Pharmacol; 2008 Apr; 51(4):380-7. PubMed ID: 18427281
[TBL] [Abstract][Full Text] [Related]
17. Acacetin causes a frequency- and use-dependent blockade of hKv1.5 channels by binding to the S6 domain.
Wu HJ; Wu W; Sun HY; Qin GW; Wang HB; Wang P; Yalamanchili HK; Wang J; Tse HF; Lau CP; Vanhoutte PM; Li GR
J Mol Cell Cardiol; 2011 Dec; 51(6):966-73. PubMed ID: 21906601
[TBL] [Abstract][Full Text] [Related]
18. Four and a half LIM protein 1: a partner for KCNA5 in human atrium.
Yang Z; Browning CF; Hallaq H; Yermalitskaya L; Esker J; Hall MR; Link AJ; Ham AJ; McGrath MJ; Mitchell CA; Murray KT
Cardiovasc Res; 2008 Jun; 78(3):449-57. PubMed ID: 18281375
[TBL] [Abstract][Full Text] [Related]
19. Effects of atorvastatin and simvastatin on atrial plateau currents.
Vaquero M; Caballero R; Gómez R; Núñez L; Tamargo J; Delpón E
J Mol Cell Cardiol; 2007 May; 42(5):931-45. PubMed ID: 17466325
[TBL] [Abstract][Full Text] [Related]
20. Potent Kv1.3 inhibitors from correolide-modification of the C18 position.
Bao J; Miao S; Kayser F; Kotliar AJ; Baker RK; Doss GA; Felix JP; Bugianesi RM; Slaughter RS; Kaczorowski GJ; Garcia ML; Ha SN; Castonguay L; Koo GC; Shah K; Springer MS; Staruch MJ; Parsons WH; Rupprecht KM
Bioorg Med Chem Lett; 2005 Jan; 15(2):447-51. PubMed ID: 15603971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]